INT207451

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 2007
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 3
Total Number 17
Disease Relevance 11.12
Pain Relevance 1.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (PLA2G7) extracellular region (PLA2G7)
Anatomy Link Frequency
heart 6
plasma 1
Platelet 1
PLA2G7 (Homo sapiens)
Pain Link Frequency Relevance Heat
cva 45 100.00 Very High Very High Very High
rheumatoid arthritis 112 99.52 Very High Very High Very High
Inflammation 103 98.44 Very High Very High Very High
Inflammatory response 14 94.92 High High
Inflammatory marker 18 93.88 High High
imagery 14 80.04 Quite High
Angina 16 29.84 Quite Low
methotrexate 6 5.00 Very Low Very Low Very Low
corticosteroid 2 5.00 Very Low Very Low Very Low
addiction 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Coronary Heart Disease 392 100.00 Very High Very High Very High
Leptospirosis 46 100.00 Very High Very High Very High
Hemorrhage 45 100.00 Very High Very High Very High
Rheumatoid Arthritis 112 99.52 Very High Very High Very High
Cancer 100 99.28 Very High Very High Very High
Stroke 252 98.80 Very High Very High Very High
INFLAMMATION 135 98.44 Very High Very High Very High
Death 101 97.28 Very High Very High Very High
Nicotine Addiction 28 96.76 Very High Very High Very High
Increased Venous Pressure Under Development 252 96.44 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We recorded roughly log-linear associations of Lp-PLA2 mass with vascular and non-vascular outcomes (figure 2 and webappendix p 11).
Lp-PLA2 Binding (associations) of
1) Confidence 0.48 Published 2010 Journal Lancet Section Body Doc Link PMC2864403 Disease Relevance 1.27 Pain Relevance 0
Cross-sectional associations of Lp-PLA2 with various markers were assessed by calculation of mean Lp-PLA2 concentrations within tenths of these characteristics, with linear mixed models adjusted for age as previously described.16 The primary outcome was coronary heart disease (ie, non-fatal myocardial infarction or fatal coronary heart disease).
Lp-PLA2 Binding (associations) of in heart associated with coronary heart disease and myocardial infarction
2) Confidence 0.48 Published 2010 Journal Lancet Section Body Doc Link PMC2864403 Disease Relevance 0.81 Pain Relevance 0.04
The strength of association for coronary heart disease with Lp-PLA2 was reduced after adjustment for baseline concentrations of lipids and apolipoproteins.
Lp-PLA2 Binding (association) of in heart associated with coronary heart disease
3) Confidence 0.48 Published 2010 Journal Lancet Section Body Doc Link PMC2864403 Disease Relevance 0.69 Pain Relevance 0.10
Furthermore, more detailed studies are needed of non-vascular outcomes, especially because recorded associations of Lp-PLA2 with risk of non-cancer, non-vascular deaths might be attributed, at least partly, to confounding by comorbidity at baseline.
Lp-PLA2 Binding (associations) of associated with cancer
4) Confidence 0.48 Published 2010 Journal Lancet Section Body Doc Link PMC2864403 Disease Relevance 0.36 Pain Relevance 0
Lp-PLA2 activity was more strongly associated with various lipid markers than was Lp-PLA2 mass, which could indicate their varying distributions across lipoprotein classes, differences in measurement precision, or both.21–23 By contrast with previous suggestions of risk thresholds,24 our analysis shows roughly log-linear associations of Lp-PLA2 with risk of coronary heart disease and total vascular mortality.
Lp-PLA2 Binding (associations) of in heart associated with coronary heart disease
5) Confidence 0.48 Published 2010 Journal Lancet Section Body Doc Link PMC2864403 Disease Relevance 0.33 Pain Relevance 0.03
As has been reported previously for CRP and fibrinogen,25,26 Lp-PLA2 is associated with risk of both major vascular and non-vascular outcomes.
Lp-PLA2 Binding (associated) of
6) Confidence 0.37 Published 2010 Journal Lancet Section Body Doc Link PMC2864403 Disease Relevance 0.57 Pain Relevance 0.08
We estimated 95% CIs from floated variances that correspond to the amount of information underlying each group (including the reference group).17 Since associations were roughly log-linear, we calculated regression coefficients to estimate the RR associated with one Z score higher Lp-PLA2, equivalent to a 1 SD higher Lp-PLA2.
Lp-PLA2 Binding (associated) of
7) Confidence 0.37 Published 2010 Journal Lancet Section Body Doc Link PMC2864403 Disease Relevance 0.14 Pain Relevance 0
We estimated 95% CIs from floated variances that correspond to the amount of information underlying each group (including the reference group).17 Since associations were roughly log-linear, we calculated regression coefficients to estimate the RR associated with one Z score higher Lp-PLA2, equivalent to a 1 SD higher Lp-PLA2.
Lp-PLA2 Binding (associated) of
8) Confidence 0.37 Published 2010 Journal Lancet Section Body Doc Link PMC2864403 Disease Relevance 0.14 Pain Relevance 0
These effects could, therefore, have blunted RRs with Lp-PLA2.
Lp-PLA2 Binding (blunted) of
9) Confidence 0.37 Published 2010 Journal Lancet Section Body Doc Link PMC2864403 Disease Relevance 0.38 Pain Relevance 0
Associations of Lp-PLA2 mass followed similar patterns, although mass was more strongly associated with smoking and less strongly associated with lipids than was activity (table 1 and webappendix p 9).
Lp-PLA2 Binding (Associations) of associated with nicotine addiction
10) Confidence 0.37 Published 2010 Journal Lancet Section Body Doc Link PMC2864403 Disease Relevance 0.53 Pain Relevance 0
Lp-PLA2 activity was more strongly associated with various lipid markers than was Lp-PLA2 mass, which could indicate their varying distributions across lipoprotein classes, differences in measurement precision, or both.21–23 By contrast with previous suggestions of risk thresholds,24 our analysis shows roughly log-linear associations of Lp-PLA2 with risk of coronary heart disease and total vascular mortality.
Lp-PLA2 Binding (associated) of in heart associated with coronary heart disease
11) Confidence 0.36 Published 2010 Journal Lancet Section Body Doc Link PMC2864403 Disease Relevance 0.38 Pain Relevance 0
Since the initial report in 2000,10 many prospective epidemiological studies have investigated the associations between circulating Lp-PLA2 (assayed either as its enzymatic activity or mass concentration) and subsequent risk of vascular disease outcomes.
Lp-PLA2 Binding (associations) of associated with increased venous pressure under development
12) Confidence 0.36 Published 2010 Journal Lancet Section Body Doc Link PMC2864403 Disease Relevance 0.73 Pain Relevance 0.21
The objective of the Lp-PLA2 Studies Collaboration,12 an analysis of individual data from relevant prospective studies, was to assess the independence, specificity, magnitude, and shape of associations of Lp-PLA2 with coronary heart disease, stroke, and mortality under different circumstances.


Lp-PLA2 Binding (associations) of in heart associated with stroke and coronary heart disease
13) Confidence 0.36 Published 2010 Journal Lancet Section Body Doc Link PMC2864403 Disease Relevance 0.72 Pain Relevance 0.09
We noted roughly log-linear associations of Lp-PLA2 activity and mass with risk of coronary heart disease and vascular death.
Lp-PLA2 Binding (associations) of in heart associated with coronary heart disease and death
14) Confidence 0.36 Published 2010 Journal Lancet Section Abstract Doc Link PMC2864403 Disease Relevance 1.13 Pain Relevance 0.03
Lipoprotein-associated phospholipase A2 activity
Lipoprotein-associated phospholipase A2 Binding (activity) of
15) Confidence 0.34 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1860077 Disease Relevance 1.28 Pain Relevance 0.27
Association of autoantibody titers against oxidized LDL and plasma lipoprotein-associated phospholipase A2 with early rheumatoid arthritis
lipoprotein-associated phospholipase A2 Binding (Association) of in plasma associated with rheumatoid arthritis
16) Confidence 0.28 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1860077 Disease Relevance 0.91 Pain Relevance 0.30
Serum Activity of Platelet-Activating Factor Acetylhydrolase Is a Potential Clinical Marker for Leptospirosis Pulmonary Hemorrhage

Pulmonary hemorrhage has been recognized as a major, often lethal, manifestation of severe leptospirosis albeit the pathogenesis remains unclear.

Platelet-Activating Factor Acetylhydrolase Spec (unclear) Binding (recognized) of in Platelet associated with leptospirosis and cva
17) Confidence 0.02 Published 2009 Journal PLoS ONE Section Title Doc Link PMC2615213 Disease Relevance 0.68 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox